Craft

BioRestorative Therapies

Stock Price

$1.5

2024-10-29

Market Capitalization

$10.6 M

2024-10-29

Revenue

$359.7 K

FY, 2025

BioRestorative Therapies Summary

Company Summary

Overview
brtxDISC (DiscImplantedStemCells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure. ThermoStem is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
Type
Public
Status
Active
Founded
1997
HQ
Melville, NY, US | view all locations
Website
http://www.biorestorative.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Lance Alstodt

    Lance Alstodt, President, CEO and Chairman of the Board

  • Robert Kristal

    Robert Kristal, Chief Financial Officer

  • Francisco Silva

    Francisco Silva, Vice President of R&D, Board Member

    • Nickolay Kukekov

    LocationsView all

    1 location detected

    • Melville, NY HQ

      United States

      40 Marcus Dr

    BioRestorative Therapies Financials

    Summary Financials

    Revenue (Q1, 2026)
    $23.2K
    Gross profit (Q1, 2026)
    $15.8K
    Net income (Q1, 2026)
    ($2.2M)
    Cash (Q1, 2026)
    $3.1M
    EBIT (Q1, 2026)
    ($3.4M)

    Footer menu